Quivax University Vaccine Against Covid-19 Shows Promising Results
Autonomous University of Querétaro Presents Biannual Report
Querétaro – In a press conference held by the Autonomous University of Querétaro (UAQ), authorities and researchers unveiled the latest developments in the Quivax university vaccine against Covid-19. The event also highlighted the significant progress made in scientific research by this esteemed institution.
Commitment to Informing Society
Dr. Teresa García Gasca, the rector of UAQ, emphasized the importance of sharing the project’s results with society. She expressed gratitude for the support received from the public and other institutions, which has been instrumental in advancing these investigations.
“We never stopped. This project was fueled by enthusiasm and dedication, and the results are truly remarkable considering the resources and conditions we had,” stated Dr. García Gasca.
Multiple Vaccine Prototypes Developed
During the presentation, Dr. Juan Joel Mosqueda Gualito, a project researcher, revealed that UAQ has successfully created five vaccine prototypes. Two of these prototypes have undergone comprehensive testing, demonstrating cellular, humoral, and neutralization responses to the variants of concern. Additionally, two protein-based vaccine prototypes for intranasal administration have shown promising humoral and cellular effects. Another prototype, based on nanoparticles, is currently under evaluation. Lastly, a messenger RNA-based vaccine against Covid-19 is being developed in collaboration with Dr. Greco Hernández from the National Institute of Cancerology and Dr. Erika Alejandra García Hernández, an RNA molecules specialist.
Contributions to Scientific Community
This research endeavor has also yielded significant academic contributions, including three theses (one for a master’s degree and two for a degree), the preparation of three scientific manuscripts, four collaboration agreements, and two postdoctoral fellowships. Furthermore, the project has been presented in four national and international conferences.
Establishment of Specialized Vaccine Development Laboratory
UAQ announced plans to establish a specialized laboratory for professional vaccine development on the Juriquilla campus by the end of this year. This laboratory will be the second of its kind in the country and the first in Querétaro, further enhancing the university’s capabilities in this field.
Financial Support and Expenditure
Dr. García Gasca provided an overview of the financial aspect, stating that UAQ has allocated over 3 million pesos from its own resources for the project. Of this amount, 503 thousand pesos were utilized in 2020, and 2.5 million pesos were spent in 2021. Additionally, the Mexican Agency for International Development Cooperation (Amexid) contributed 3.3 million pesos, while 6.6 million pesos were obtained from various sources, including vaccination campaigns and other events.
These funds have been utilized for the acquisition of materials and reagents, laboratory equipment, complementary services, equipment maintenance, professional fees, laboratory adjustments, and scientific laboratory analysis services. As of June 2023, UAQ has expended a total of 12.2 million pesos, with 797 thousand pesos remaining for committed expenses. In total, the university has contributed 13 million pesos to this cause. Dr. García Gasca emphasized the significance of these results, as they pave the way for the development of chimeric vaccines, a field that only a few institutions worldwide have explored.
External Audit and Final Report
The university authorities assured that an external office will conduct an audit of the project’s finances. Once all the resources have been accounted for, a final report will be prepared by November.
The following individuals played key roles in this research: Mr. Luis Alberto Fernández García, Private Secretary, and the scientists leading the investigation: Dr. Diego Josimar Hernandez Silva, Dr. Dra. Lineth Juliana Vega Rojas, and Mr. Miguel Andrés Velazco Elizondo.
Ed vaccine development laboratory to further enhance its research capabilities in vaccine development. This laboratory will provide state-of-the-art facilities and equipment for researchers to continue their work in developing effective vaccines against Covid-19 and other infectious diseases.
Clinical Trials and Approval Process
Dr. Mosqueda Gualito highlighted the importance of conducting clinical trials to assess the safety and efficacy of the Quivax university vaccine. The research team is in the process of obtaining the necessary approvals from regulatory authorities to initiate these trials. Once the clinical trials are completed and the vaccine is proven to be safe and effective, it can be made available to the public.
Hope for the Future
The unveiling of the Quivax university vaccine and the progress made by UAQ in scientific research signify a source of hope in the fight against Covid-19. The dedication and commitment of the researchers at UAQ, coupled with the support received from the public and other institutions, provide optimism for the development of effective vaccines and the eventual control of the pandemic.
The Autonomous University of Querétaro has made significant progress in developing the Quivax university vaccine against Covid-19. The unveiling of multiple vaccine prototypes, the establishment of a specialized vaccine development laboratory, and the dedication of researchers demonstrate the institution’s commitment to advancing scientific research and finding solutions to the global health crisis. With further clinical trials and regulatory approvals, the Quivax university vaccine has the potential to contribute to the control and eventual eradication of Covid-19.
What specific features and equipment will the Ed vaccine development laboratory have to enhance vaccine development research at UAQ?
The Ed vaccine development laboratory at UAQ will be equipped with cutting-edge features and equipment to enhance vaccine development research. Some specific features and equipment may include:
1. Biosafety Cabinets: These cabinets ensure the safety of researchers by providing a contained and sterile environment for working with infectious materials.
2. Real-time PCR Machines: These machines are used for the detection and quantification of specific genetic material, allowing researchers to measure the effectiveness of vaccines.
3. Flow Cytometers: Flow cytometers analyze and sort cells based on their physical and chemical characteristics, which can help in studying vaccine responses at the cellular level.
4. Cell Culture Facilities: These facilities will allow researchers to grow and maintain cells, including virus-infected cells, for studying vaccine efficacy and viral replication.
5. Imaging Systems: Advanced imaging systems, such as confocal microscopes, will enable researchers to visualize the interactions between vaccines and target cells at a higher resolution.
6. High-Throughput Screening Platforms: These automated platforms can rapidly test the efficacy of various vaccine candidates against different pathogens, greatly speeding up the vaccine development process.
7. Animal Model Facilities: The lab may have dedicated facilities to house and study animal models, such as mice or non-human primates, to assess vaccine safety and effectiveness.
8. Bioinformatics Tools: Specialized software and computing resources will be available for analyzing large datasets generated during vaccine research, including genomic and proteomic data.
9. In vitro Assay Platforms: The lab may have platforms for testing vaccine-induced immune responses, such as ELISA assays or neutralization assays, to evaluate vaccine potency.
10. Collaborative Spaces: The lab may be designed to encourage collaboration and exchange of ideas among researchers, with dedicated spaces for discussions, meetings, and seminars.
These features and equipment will enable UAQ researchers to conduct comprehensive and innovative vaccine development research, ultimately contributing to global health initiatives.